Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

The heightened importance of the microbiome in cancer immunotherapy: Trends in Immunology

Frontiers Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B- cell lymphomas

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies - Kampouri - 2023 - Transplant Infectious Disease - Wiley Online Library

The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies, Cell & Bioscience

PDF) CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Frontiers Emerging roles of the gut microbiota in cancer immunotherapy

Frontiers The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy: Molecular Therapy

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies - Kampouri - 2023 - Transplant Infectious Disease - Wiley Online Library

Frontiers Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail? - ScienceDirect

Frontiers CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure